Karen H Costenbader1, Lindsey A MacFarlane2, I-Min Lee3,4, Julie E Buring3,4, Samia Mora3,5, Vadim Bubes3, Gregory Kotler3, Carlos A Camargo4,6, JoAnn E Manson3,4, Nancy R Cook3,4. 1. Division of Rheumatology, Inflammation and Immunity, and kcostenbader@bwh.harvard.edu. 2. Division of Rheumatology, Inflammation and Immunity, and. 3. Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 4. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA. 5. Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 6. Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Abstract
BACKGROUND: Observational studies suggest vitamin D and marine ω-3 fatty acid (n-3 FA) supplements are associated with lower systemic inflammation. However, past trials have been inconsistent. METHODS: The randomized, double-blind, placebo-controlled VITamin D and OmegA-3 TriaL (VITAL) tested vitamin D (2000 IU/day) and/or n-3 FA (1 g/day) supplementation in a 2 × 2 factorial design among women ≥55 and men ≥50 years of age. We assessed changes in interleukin (IL)-6, tumor necrosis factor receptor 2 (TNFR2), and high-sensitivity C-reactive protein (hsCRP) concentrations from baseline to 1 year among participants randomized to vitamin D + n-3 FA (392), vitamin D (392), n-3 FA (392), or placebo only (385). Geometric means and percent changes were compared, adjusting for baseline factors. RESULTS: Baseline characteristics were well balanced. In the active arms, 25-OH vitamin D rose 39% and n-3 FA rose 55% vs minimal change in placebo arms. Neither supplement reduced biomarkers at 1 year. Vitamin D resulted in 8.2% higher IL-6 (95% CI, 1.5%-15.3%; adjusted P = 0.02), but TNFR2 and hsCRP did not. Among 784 receiving vitamin D, hsCRP increased 35.7% (7.8%-70.9%) in those with low (<20 ng/mL) but not with higher baseline serum 25(OH) vitamin D [0.45% (-8.9% to 10.8%); P interaction = 0.02]. Among 777 randomized to n-3 FA, hsCRP declined [-10.5% (-20.4% to 0.8%)] in those with baseline low (<1.5 servings/week), but not with higher fish intake [6.4% (95% CI, -7.11% to 21.8%); P interaction = 0.06]. CONCLUSIONS: In this large sample from a population-based randomized controlled trial, neither vitamin D nor n-3 FA supplementation over 1 year decreased these biomarkers of inflammation. CLINICALTRIALSGOV IDENTIFIER: NCT01169259; NCT01351805.
BACKGROUND: Observational studies suggest vitamin D and marine ω-3 fatty acid (n-3 FA) supplements are associated with lower systemic inflammation. However, past trials have been inconsistent. METHODS: The randomized, double-blind, placebo-controlled VITamin D and OmegA-3 TriaL (VITAL) tested vitamin D (2000 IU/day) and/or n-3 FA (1 g/day) supplementation in a 2 × 2 factorial design among women ≥55 and men ≥50 years of age. We assessed changes in interleukin (IL)-6, tumor necrosis factor receptor 2 (TNFR2), and high-sensitivity C-reactive protein (hsCRP) concentrations from baseline to 1 year among participants randomized to vitamin D + n-3 FA (392), vitamin D (392), n-3 FA (392), or placebo only (385). Geometric means and percent changes were compared, adjusting for baseline factors. RESULTS: Baseline characteristics were well balanced. In the active arms, 25-OH vitamin D rose 39% and n-3 FA rose 55% vs minimal change in placebo arms. Neither supplement reduced biomarkers at 1 year. Vitamin D resulted in 8.2% higher IL-6 (95% CI, 1.5%-15.3%; adjusted P = 0.02), but TNFR2 and hsCRP did not. Among 784 receiving vitamin D, hsCRP increased 35.7% (7.8%-70.9%) in those with low (<20 ng/mL) but not with higher baseline serum 25(OH) vitamin D [0.45% (-8.9% to 10.8%); P interaction = 0.02]. Among 777 randomized to n-3 FA, hsCRP declined [-10.5% (-20.4% to 0.8%)] in those with baseline low (<1.5 servings/week), but not with higher fish intake [6.4% (95% CI, -7.11% to 21.8%); P interaction = 0.06]. CONCLUSIONS: In this large sample from a population-based randomized controlled trial, neither vitamin D nor n-3 FA supplementation over 1 year decreased these biomarkers of inflammation. CLINICALTRIALSGOV IDENTIFIER: NCT01169259; NCT01351805.
Authors: Ashwin N Ananthakrishnan; Hamed Khalili; Gauree G Konijeti; Leslie M Higuchi; Punyanganie de Silva; Charles S Fuchs; Walter C Willett; James M Richter; Andrew T Chan Journal: Gut Date: 2013-07-04 Impact factor: 23.059
Authors: Deepak L Bhatt; P Gabriel Steg; Michael Miller; Eliot A Brinton; Terry A Jacobson; Steven B Ketchum; Ralph T Doyle; Rebecca A Juliano; Lixia Jiao; Craig Granowitz; Jean-Claude Tardif; Christie M Ballantyne Journal: N Engl J Med Date: 2018-11-10 Impact factor: 91.245
Authors: S A Kliewer; S S Sundseth; S A Jones; P J Brown; G B Wisely; C S Koble; P Devchand; W Wahli; T M Willson; J M Lenhard; J M Lehmann Journal: Proc Natl Acad Sci U S A Date: 1997-04-29 Impact factor: 11.205
Authors: Paulette D Chandler; Jamil B Scott; Bettina F Drake; Kimmie Ng; Joann E Manson; Nader Rifai; Andrew T Chan; Gary G Bennett; Bruce W Hollis; Edward L Giovannucci; Karen M Emmons; Charles S Fuchs Journal: Cancer Prev Res (Phila) Date: 2013-12-10
Authors: Shari S Bassuk; JoAnn E Manson; I-Min Lee; Nancy R Cook; William G Christen; Vadim Y Bubes; David S Gordon; Trisha Copeland; Georgina Friedenberg; Denise M D'Agostino; Claire Y Ridge; Jean G MacFadyen; Kate Kalan; Julie E Buring Journal: Contemp Clin Trials Date: 2016-01-06 Impact factor: 2.226
Authors: Rosangela A Hoshi; Yanyan Liu; Mohit Jain; Daniel I Chasman; Olga V Demler; Samia Mora; Heike Luttmann-Gibson; Saumya Tiwari; Franco Giulianini; Allen M Andres; Jeramie D Watrous; Nancy R Cook; Karen H Costenbader; Olivia I Okereke; Paul M Ridker; JoAnn E Manson; I-Min Lee; Manickavasagar Vinayagamoorthy; Susan Cheng; Trisha Copeland Journal: Circ Res Date: 2022-07-19 Impact factor: 23.213
Authors: Jill Hahn; Nancy R Cook; Erik K Alexander; Sonia Friedman; Joseph Walter; Vadim Bubes; Gregory Kotler; I-Min Lee; JoAnn E Manson; Karen H Costenbader Journal: BMJ Date: 2022-01-26
Authors: Christine P Limonte; Leila R Zelnick; John Ruzinski; Andrew N Hoofnagle; Ravi Thadhani; Michal L Melamed; I-Min Lee; Julie E Buring; Howard D Sesso; JoAnn E Manson; Ian H de Boer Journal: Diabetologia Date: 2020-10-24 Impact factor: 10.122
Authors: Olga V Demler; Yanyan Liu; Heike Luttmann-Gibson; Jeramie D Watrous; Kim A Lagerborg; Hesam Dashti; Franco Giulianini; Mallory Heath; Carlos A Camargo; William S Harris; Jay G Wohlgemuth; Allen M Andres; Saumya Tivari; Tao Long; Mahan Najhawan; Khoi Dao; James G Prentice; Julia A Larsen; Olivia I Okereke; Karen H Costenbader; Julie E Buring; JoAnn E Manson; Susan Cheng; Mohit Jain; Samia Mora Journal: Metabolites Date: 2020-10-27